TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Men and women aged 18 to 69 years, with elevated cholesterol levels may be eligible to participate in a research study to assess the efficacy and safety of two marketed drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Buen Provecho!: A Virtual Family-Based Intervention to Promote Health

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria include:~1. Child is clients at community clinic~2. Child between the ages 6-12 years~3. Child has a BMI percentage greater than 85%~4. Primary parent or guardian is \> 18 years of age~5. Family identifies as Hispanic and Spanish is one of the primary languages spoken in the home~6. Children will be living with the primary guardian or parent for the duration of the program~7. Access to the internet~8. Parent or guardian is willing to commit to engaging in the 12 week program~Exclusion Criteria:~1. Family plans to change location within the year~2. During initial screening for the study, the study PI determines that the intervention may exacerbate existing medical conditions of the child or the family.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): 12 week virtual family-based health eating program
- Comparison (Type: NO_INTERVENTION): Standard in-office counseling about diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of UC as confirmed by endoscopic or histologic criteria as established by RomeIII~* Disease activity score of \>5 and ≤13 according to the Simple clinical colitis activity index (SCCAI)~* Patient on stable 5 ASA medication dose for at least 4 weeks prior to inclusion~* Patients who receive immunosuppressant or biological therapy (azathioprine, 6-mercaptopurine, infliximab or methotrexate) must be on stable dose for at least 3 months prior to inclusion~* Patients who receive topical therapy (5ASA or steroidal), must be on stable dose for a least 2 weeks prior to inclusion~* Patient had hemoglobin of \>10 g/dl.~* Able and willing to give written consent~Exclusion Criteria:~* Patient with renal or liver disease, sever cardiovascular disease, chronic pancreatitis, diabetes mellitus or gallstone.~* Patient with laboratory abnormalities indicating anemia (hemoglobin \<10), leucopenia, thrombocytopenia, abnormal coagulation.~* Patient with infection, sepsis or pneumonia.~* Pregnant or nursing women.~* Unable or unwilling to receive CURCUMIN therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatments arm (Type: ACTIVE_COMPARATOR): Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
- Control arm (Type: PLACEBO_COMPARATOR): Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Dexamethasone for Ropivacaine Axillary Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA 1,2 et 3~* surgery under axillary brachial plexus block~* aged \>18 years~* signed information consent~Exclusion Criteria:~* impaired coagulation~* contraindication to regional anesthesia or technical impossibility~* opioids or pain killers abuse or addiction~* steroids consumption in the past 6 months~* dementia or under administrative supervision~* delay of surgery to short to allow regional anesthesia~* pregnancy and breastfeeding~* allergy and contraindication to dexamethasone or ropivacaine~* anticipated bad observation of treatment~* patient enrolled in another trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intravenous dexamethasone (Type: ACTIVE_COMPARATOR): intravenous injection of 8mg (2ml) of dexamethasone during regional anesthesia
- intravenous placebo (Type: PLACEBO_COMPARATOR): intravenous injection of 2ml of NaCl 0.9% during regional anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 8 - 17 years of age with a history of migraine meeting the criteria established in ICHD-II (2004), Section 1. Patients will provide at least 28-day baseline data in the form in the daily diary and must have at least 15 days of reported headache during this period, with at least 4 distinct episodes lasting at least 4 hours each.~Exclusion Criteria:~* Previous use of botulinum toxin of any serotype for any reason~* Pregnancy.~* Diagnosis of Myasthenia gravis, Eaton Lambert Syndrome, Amyotrophic Lateral Sclerosis~* Treatment of headache using acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints, or injection of anesthetics/steroids within 4 weeks prior to the week of screening visit

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA/Saline Placebo (Type: OTHER): The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
- Saline Placebo/OnabotulinumtoxinA (Type: OTHER): The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients ( \> 18 years) requiring surgical intervention within 24 hours of diagnosis, for localized IAI infections (i.e extending beyond the organ wall but confined near the hollow viscus, mild to moderate in severity):~* Acute appendicitis: Ruptured or perforated with abscess~* Acute diverticulitis with perforation and/or abscess~* Acute cholecystitis (including gangrenous) with either rupture or perforation~* Acute gastric and duodenal ( \> 24 hours) perforation~* Traumatic (\> 12 hours) perforation of the intestines~* Secondary peritonitis due to perforated viscus~* Intra-abdominal abscess (including of liver and spleen)~Exclusion Criteria:~* Traumatic bowel perforation requiring surgery within 12 hours~* Perforation of gastroduodenal ulcers requiring surgery within 24 hours~* other intra-abdominal processes in which the primary etiology was unlikely to be infectious.~* Patients lactating or pregnant~* Patients with a history of allergy, hypersensitivity, or any severe reaction to the study antibiotics~* Patients with rapidly progressive or terminal illness;~* Patients with a history or presence of severe hepatic or renal disease (e.g. creatinine clearance \< 0.5 ml/min/1.73 m2);~* Patients with a concomitant infection that would interfere with evaluation of response to the study antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E (Type: EXPERIMENTAL): 3 days regimen with Ertapenem
- AS (Type: ACTIVE_COMPARATOR): 3 days treatment with Ampicillin-Sulbactam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Therapy Plus Naltrexone for Alcoholism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meets criteria for alcohol dependence, has not had more than one previous inpatient medical detoxification.~* Consumes on average five standard drinks per day.~* Able to maintain sobriety for five days (with or without the aid of detoxification medications) as determined by self-report, collateral report, and breathalyzer measurements.~* Able to read and understand questionnaires and informed consent.~* Lives within 50 miles of the study site.~Exclusion Criteria:~* Currently meets criteria for any other psychoactive substance dependency disorder.~* Ever abused opiates.~* Used psychoactive substance abuse, except marijuana, within the last 30 days as evidenced by patient report, collateral report, and urine drug screen.~* Meets criteria for disorders of major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress syndrome, bipolar affective disorder, schizophrenia, or any other psychotic disorder or organic mental disorder.~* Meets criteria for dissociate disorder or eating disorders.~* Has current suicidal or homicidal ideation.~* Need for maintenance or acute treatment with any psychoactive medication including antiseizure medications.~* Current use of disulfiram (Antabuse).~* Clinically significant medical problems that would impair participation or limit medication ingestion.~* Hepatocellular disease.~* Sexually active females of child bearing potential who are pregnant, nursing, or who are not using a reliable form of birth control.~* Have current charges pending for a violent crime.~* Does not have a stable living situation and a reliable source of collateral reporting.~* Has taken an opiate antagonist drug in the last month.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who met the DSM-IV criteria for a primary diagnosis of ADHD of any subtype (may have been newly diagnosed with ADHD and not on treatment)~* score of 24 or higher on the ADHD Rating Scale (ADHD-RS) at screening~* physician must have rated the patient as Moderately ill or worse on the CGI-S at screening~* children may have been enrolled who were not receiving adequate treatment for ADHD (based on clinical judgment in consultation with the parent)~* children must have been washed-out of their current treatment a minimum of 3 days or 5 half lives of the medication whichever was longer~* and the child and parent must have given written informed consent, and assent, where applicable.~Exclusion Criteria:~* Female child who had experienced menarche~* presence of eating or substance disorder or co-morbid psychiatric condition other than oppositional defiant disorder~* history of seizure, tic disorder, mental retardation, severe developmental disorder (i.e. severe cerebral palsy, autism) or family history of Tourette's Disorder~* required medications as excluded by the package inserts for Concerta or Strattera~* diagnosed with hyperthyroidism or glaucoma~* and known non-responders to treatments indicated for ADHD.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Lifitegrast to Treat Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to read, sign and date the informed consent and HIPAA documents~* Willing and able to comply with all study procedures~* Be at least 18 years of age~* Patient-reported history of dry eye in both eyes~* A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period~Exclusion Criteria:~* Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy~* Unwilling to avoid wearing contact lenses for 24h prior to Visit 1 and for some duration during the study~* Any blood donation or significant loss of blood within 56 days of Visit 1~* Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.~* Use of any prohibited medications during the appropriate pre-study washout period and at any time during the study unless otherwise specified~* Any significant illness that could interfere with study parameters~* History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.~* Known history of alcohol and/or drug abuse~* Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Lifitegrast (Type: EXPERIMENTAL): Active

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Urinary albumin excretion of ≤3000 μg of creatinine~2. Stage 3 CKD~3. Plasma iPTH: \> 70 pg/mL and \< 500 pg/mL~4. Serum Ca: ≥ 8.4 mg/dL and \< 10.0 mg/dL~5. Serum P: ≥ 2.0 mg/dL and \< 5.0 mg/dL~6. Serum 25-hydroxyvitamin D: \> 10 ng/mL and \< 29 ng/mL.~7. Discontinue vitamin D use for duration of study~Exclusion Criteria:~1. History of kidney transplant or parathyroidectomy~2. Spot urine calcium:creatinine ratio \> 0.2~3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event or hepatitis~4. Currently on dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: CTAP101 Capsules 60µg (Type: EXPERIMENTAL): None
- Cohort 1: CTAP101 Capsules 90µg (Type: EXPERIMENTAL): None
- Cohort 1: Sugar Capsule (Type: PLACEBO_COMPARATOR): None
- Cohort 2: CTAP101 Capsules 30µg (Type: EXPERIMENTAL): None
- Cohort 2: Sugar Capsule (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Volatile Anesthetics for Hepatic Protection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years of age~* Patients undergoing liver resection (benign or malignant tumors)~Exclusion Criteria:~* Laparoscopic liver resection coagulopathy (platelets \< 50,000/ml, Quick \< 50%)~* Liver cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or Metastatic renal cell carcinoma (RCC)~* Predominant clear cell histology:~  1. At least 1 but no more than 2 prior systemic anti vascular endothelial growth factor (anti-VEGF) treatments~ 2. No more than 3 total prior systemic treatment regimens in the advanced or metastatic setting~ 3. Subjects with prior treatment with a mechanistic target of rapamycin (mTOR) are eligible~* Non-clear cell histology: 0-3 prior systemic therapies and may include mTOR inhibitor~* Brain metastases allowed if asymptomatic, without edema, and not receiving corticosteroids or radiation~* Performance Status (PS): ≥ 70% Karnofsky Performance Scale (KPS)~* All Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic scores allowed~Exclusion Criteria:~* Subjects with any active autoimmune disease or a history of known autoimmune disease~* History of severe hypersensitivity reaction to other monoclonal antibodies~* Prior malignancy, active within the last 3 years, except for locally curable cancers which have been apparently cured~* Known HIV or AIDS-related illness~* Any positive tests for Hepatitis B or Hepatitis C virus indicating acute or chronic infection~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Type: EXPERIMENTAL): Nivolumab dose as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluation~2. Age 18 years or older~3. Body weight ≥ 35 kg~4. Subjects must have histologically or cytologically documented NSCLC who present with locally advanced, unresectable, Stage III disease~5. Subjects must have completed, without progressing, definitive cCRT within 42 days prior to being randomized into the study~6. Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy~7. Life expectancy ≥ 12 weeks~8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~9. Subjects must have at least one previously irradiated tumor lesion that can be measured by RECIST v1.1~Main Exclusion Criteria:~1. Mixed small cell and non-small cell lung cancer histology~2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug~3. Prior exposure to any anti-PD1, anti-PD-L1, or anti-CTLA4 antibody for treatment of NSCLC~4. Subjects with history of ≥ Grade 2 pneumonitis from prior chemoradiation therapy~5. Subjects with a history of venous thrombosis within the past 3 months~6. Subjects with history of myocardial infarction, transient ischemic attack, or stroke in the past 6 months~7. Congestive heart failure~8. Active or prior documented autoimmune or inflammatory disorders~9. History of active primary immunodeficiency~10. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)~11. History of allogenic organ transplantation~12. QTcF interval ≥ 470 ms~13. History of another primary malignancy~14. Concurrent enrollment in another clinical study \[concurrent enrollment in an observational (non-interventional) clinical study or during the follow-up period of an interventional study is permitted\]~15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Durvalumab monotherapy) (Type: EXPERIMENTAL): durvalumab IV
- Arm A (durvalumab + oleclumab): (Type: EXPERIMENTAL): durvalumab IV and oleclumab IV
- Arm B (durvalumab + monalizumab) (Type: EXPERIMENTAL): durvalumab IV and monalizumab IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete